Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | HAT1 | O14929 | 5/20 | 0.35 |
| ▸ | EP300 | Q09472 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804065 | 0.83 | CSNK1A1 (0.34) | CYP11B2HAT1EP300CYP19A1CSNK1A1 | |
| SCHEMBL17032988 | 0.78 | CYP11B2 (0.39) | CYP11B2CYP2A6EGLN2KDM4ECYP19A1 | |
| SCHEMBL20229602 | 0.78 | HAT1 (0.42) | HAT1EP300 | |
| SCHEMBL17453430 | 0.76 | EIF4A3 (0.43) | HAT1EP300KDM4E | |
| SCHEMBL23425908 | 0.76 | EPHB3 (0.42) | KDM4ECSNK1A1CSNK1DMAPK14 | |
| SCHEMBL17452697 | 0.75 | HAT1 (0.48) | HAT1EP300 | |
| SCHEMBL24566030 | 0.75 | CA12 (0.38) | CYP11B2PGRCYP19A1CSNK1A1CSNK1D | |
| SCHEMBL25099101 | 0.75 | EPHB3 (0.43) | KDM4E | |
| SCHEMBL12728992 | 0.75 | DRD4 (0.36) | — | |
| SCHEMBL23133667 | 0.75 | KCNH2 (0.37) | KDM4EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | CYP11B2 3248/4885CYP2A6 4003/4885EGLN2 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.